Comparative Pharmacology
Head-to-head clinical analysis: DUTOPROL versus LOPRESSIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTOPROL versus LOPRESSIDONE.
DUTOPROL vs LOPRESSIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of metoprolol tartrate (beta-1-selective adrenergic receptor blocker) and hydrochlorothiazide (thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule).
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
1 tablet (containing 12.5 mg hydrochlorothiazide and 50 mg losartan) orally once daily; may increase to 1 tablet (12.5 mg/100 mg) once daily if inadequate response.
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
None Documented
None Documented
Bisoprolol: 10-12 hours, allowing once-daily dosing; Hydrochlorothiazide: 6-15 hours, prolonged in renal impairment.
12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days.
Renal: 40-50% as unchanged drug and metabolites (hydrochlorothiazide and bisoprolol); Fecal/Biliary: <15%.
Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination